FeedingTrends
Mycoplasma Detection Systems Market: Global Forecast Over 2032
6 months ago
1 min read

Mycoplasma Detection Systems Market: Global Forecast Over 2032

The global mycoplasma detection systems market is likely to be valued at US$ 600 Million in FY 2022, up from US$ 560 Million in 2021. During the past year, the industry registered a Y-o-Y increase worth 7.1%. From 2022 to 2032, mycoplasma detection systems sales are poised to flourish at a CAGR of 9.6% to reach a value of US$ 1.5 Billion by the end of 2032.

Mycoplasma detection systems are in high demand in the biotechnology and pharmaceutical sectors. These systems are used to detect the presence of mycoplasma contamination in cell culture, bioburden and raw material testing processes. Mycoplasma contamination can cause significant problems in biopharmaceutical processes, leading to reduced product yields, loss of cell viability and lower product quality. As such, the demand for mycoplasma detection systems is expected to increase in the coming years as companies look to ensure the quality and safety of their products.

Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=446?pk

Key Companies

  • Agilent Technologies

  • Abbott

  • Eurofins Scientific

  • Charles River Laboratories International Inc.

  • F. Hoffmann-La Roche Ltd

  • Lonza Group

  • PromoCell GmbH

  • Merck KGaA

Competitive Landscape

Prominent Mycoplasma detection systems providers are reliant on partnerships, collaborations, acquisitions, and new software launches so as to stay afloat in the global market. Constant innovations to ensure a seamless client-customer relationship are the main focus of prominent market players.

  • In June 2021, Agilent Technologies Inc. announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software in addition to Agilent’s portfolio of automated pathology staining solutions.

  • In Nov 2021, Merck KGaA, a leading science and technology company, announced the completion of its $17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $ 130 billion global industry to help solve the toughest problems in life science.

Key Segments Covered in the Mycoplasma Detection Systems Industry Survey

  • Mycoplasma detection systems by Product Type

  • Mycoplasma detection systems Kits and Reagents

  • Nucleic Acid Detection Kits

  • PCR Assays

  • Elimination Kits & Reagents

  • Others

  • Mycoplasma Detection Services

  • Mycoplasma Detection Systems

  • PCR Based Systems

  • Luminescence Based Systems

  • Mycoplasma Detection Systems by Technique

  • PCR Mycoplasma detection systems

  • ELISA Mycoplasma detection systems

  • Direct & Indirect Assay Mycoplasma detection systems

  • Others

  • Mycoplasma Detection Systems by End User

  • Mycoplasma Detection Systems in Pharmaceutical & Biopharmaceutical Companies

  • Mycoplasma detection systems in Research Laboratories

  • Mycoplasma detection systems in Contract Research Organizations (CROs)

  • Mycoplasma detection systems in Academic Research Institutes

  • Mycoplasma Detection Systems by Region

  • North America

  • Latin America

  • Europe

  • Asia Pacific

  • Middle East & Africa

Appreciate the creator